SQUID-DERIVED PEPTIDES AND USES THEREOF

• Main Authors: JO, Seon Mi, JUNG, Seung Hyun, BAEK, Kyung Hwa, LEE, Jei Ha, KIM, Hea Bin, KIM, Ki Hyun, CHOI, Jeong Hyeon, SONG, Ha Yeun, CHOI, Tae Young
• Format: Patent
• Language: English; French; Korean
• Published: 22.06.2023
• Subjects: CHEMISTRY; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The present invention relates to squid-derived peptides and uses thereof and, more specifically, to uses of squid-derived peptides squidtocin and prosepiatocin for prevention or treatment of V1B receptor-related diseases. It has been confirmed that the squidtocin and prosepiatocin according to the present invention have an effect of inducing activation of a V1B receptor which is a type of vasopressin receptor. The V1B receptor which is a type of vasopressin receptor is present in the anterior pituitary and in the hippocampal CA2 region, and it is known that the V1B receptor increases intracellular calcium concentration and is involved in response to stress and sociality. Accordingly, the squidtocin and prosepiatocin according to the present invention can be used in various ways in the field of prevention, amelioration, or treatment of V1B receptor-related diseases. La présente invention concerne des peptides dérivés de calmar et leurs utilisations et, plus particulièrement, des utilisations de peptides dérivés de calmar et de la prosépiatocine pour la prévention ou le traitement de maladies associées au récepteur V1B. Il a été confirmé que la squidtocine et la prosépiatocine selon la présente invention ont pour effet d'induire l'activation d'un récepteur V1B qui est un type de récepteur de la vasopressine. Le récepteur V1B qui est un type de récepteur de vasopressine est présent dans la région pituitaire antérieure et dans la région CA2 hippocampique, et il est connu que le récepteur V1B augmente la concentration de calcium intracellulaire et est impliqué dans la réponse au stress et à la sociabilité. Par conséquent, la squidtocine et la prosépiatocine selon la présente invention peuvent être utilisées de diverses manières dans le domaine de la prévention, de l'amélioration ou du traitement de maladies associées au récepteur V1B. 본 발명은 오징어 유래 펩타이드 및 이의 용도에 관한 것으로, 보다 상세하게는 오징어 유래 펩타이드인 스퀴드토신 및 프로세피아토신의 V1B 수용체 관련 질환의 예방 또는 치료 용도에 관한 것이다. 본 발명에 따른 스퀴드토신 및 프로세피아토신은 바소프레신 수용체의 일종인 V1B 수용체의 활성화를 유도하는 효과가 있음을 확인하였다. 상기 바소프레신 수용체인 V1B 수용체는 뇌하수체 전엽과 해마 CA2 영역에 존재하며, 세포 내 칼슘 농도를 상승시키고 스트레스에 대한 반응 및 사회성에 관여한다고 알려져 있다. 따라서 본 발명에 따른 스퀴드토신 및 프로세피아토신은 V1B 수용체 관련 질환의 예방, 개선 또는 치료 분야에서 다양하게 활용될 수 있다.